Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D

globenewswire

Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D – NEWSnet – News… as it used to be

More Press Releases

June 20, 2026

Ohio University President Lori Stewart Gonzalez to Keynote WIIC 2026 Healthcare & Innovation Summit

June 20, 2026

LIKE85 Announces RISKY BLUE, a New Ambroxan-Driven Fragrance Inspired by Electric Skin

June 20, 2026

Cryptocurrency News: Pepeto Nears Exchange Listing while the Cardano Price Prediction Could Flip After Hoskinson’s June Move

June 20, 2026

Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D

Ohio University President Lori Stewart Gonzalez to Keynote WIIC 2026 Healthcare & Innovation Summit

LIKE85 Announces RISKY BLUE, a New Ambroxan-Driven Fragrance Inspired by Electric Skin

Cryptocurrency News: Pepeto Nears Exchange Listing while the Cardano Price Prediction Could Flip After Hoskinson’s June Move

New Crypto: Pepeto Confirms DeFi Progress Follow Dogecoin Success While the Ethereum Price Prediction Targets $7,000